RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine.
Celia Romero Del RincónAlicia Gonzalez-MartinezSonia QuintasDavid Garcia AzorinIris Fernández LázaroÁngel Luis Guerrero-PeralYesica Gonzalez OsorioSonia Santos-LasaosaCarmen González OriaNorberto Sánchez RodríguezFernando Iglesias DíezAna Echavarría ÍñiguezSendoa Gil LuqueMariano Huerta-VillanuevaSergio Campoy DíazAlbert Muñoz-VendrellAlberto Lozano RosAntonio Sánchez-SoblecheroFernando Velasco JuanesIzaro Kortazar-ZubizarretaAmaya EcheverríaJaime Rodríguez-VicoAlex Jaimes SánchezAndrea Gómez GarcíaNoemí Morollón Sánchez-MateosRobert BelvisMaría Pilar Navarro-PérezJuan Carlos García-MoncóMaría Rocío Álvarez EscuderoNuria MontesAna Beatriz Gago-VeigaPublished in: European journal of neurology (2024)
The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.